EPS Creative Health Technology (Stock Code: 3860) Announces Interim Results for the Six Months Ended 30 September 2025

Bulletin Express
Nov 27, 2025

EPS Creative Health Technology reported revenue of approximately HK$223.9 million for the six months ended 30 September 2025, compared with HK$346.9 million over the same period last year. The Group recorded a loss after taxation of around HK$2.6 million, versus a profit of HK$17.1 million in the corresponding period in 2024. Basic loss per share stood at 0.78 HK cent based on a weighted average of 522,177,419 shares, and the Board has not proposed an interim dividend.

According to the announcement, the Healthcare and Medicated Products Business posted a notable increase in segment revenue to HK$101.7 million, compared with HK$73.4 million a year earlier. The segment’s performance was supported by growth in its health and medicated food distribution business and by large-scale projects in its laboratory supply distribution business. The IRO with CRO Service and In-house R&D Business recorded revenue of HK$45.4 million, up from HK$28.5 million, attributed in part to the China-focused specialised CRO services. By contrast, garment segment revenue declined from HK$245.0 million to HK$76.9 million, primarily due to reduced orders from major customers in the United States and Europe.

Gross profit reached HK$37.8 million, compared with HK$49.6 million in the previous year. Segment-wise, the Healthcare and Medicated Products Business benefited from new sales channels and improved cost controls. The IRO with CRO Service saw revenue expansion but reported reduced gross profit, owing to a narrower focus in certain service areas. Within the garment segment, despite lower sales volume, cost control and higher average selling prices of womenswear and menswear helped lift the gross margin.

As of 30 September 2025, the Group had net current assets of HK$70.7 million and a gearing ratio of 0.03. Management highlighted that future strategies will focus on strengthening and expanding the core businesses—particularly in healthcare-related distribution and IRO with CRO services—while continuing to maintain a prudent approach and efficient resource use in the garment segment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10